PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0.98) by 15.65 percent. This is a 35.66 percent increase over losses of $(1.29) per share from the same period last year. The company reported quarterly sales of $178.88 million which beat the analyst consensus estimate of $171.46 million by 4.33 percent. This is a 4.19 percent decrease over sales of $186.70 million the same period last year.